Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Market Closed - Nyse Other stock markets 04:00:02 2026-06-05 pm EDT			5-day change	1st Jan Change
57.27 ^USD	+1.18%		+0.16%	+6.17%

Jun. 03	Arcus Biosciences Partners With Bristol Myers Squibb to Develop Kidney Cancer Treatment	MT
Jun. 03	Arcus to Supply Experimental Kidney Cancer Drug for Myers Squibb Trial	DJ

Transcript : Bristol-Myers Squibb Company Presents at Bank of America Global Healthcare Conference 2026, May-14-2026 08

Published on 05/14/2026 at 01:05 pm EDT - Modified on 05/14/2026 at 02:35 pm EDT

S&P Capital IQ

Presenter Speech
Jason Gerberry (Analysts)

All right, everybody. We're going to get going here with our next company presenter at the BofA Annual Healthcare Conference. My name is Jason Gerberry. I

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Bristol-Myers Squibb Company

Jun. 03	Arcus Biosciences Partners With Bristol Myers Squibb to Develop Kidney Cancer Treatment	MT
Jun. 03	Arcus to Supply Experimental Kidney Cancer Drug for Myers Squibb Trial	DJ
Jun. 03	Arcus Biosciences, Inc. and Bristol Myers Squibb Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD-L1/VEGF-A Bispecific Immunomodulator to Treat Kidney Cancer	CI
Jun. 03	HEALTH ROUNDS-Radiation-emitting implant improves outcomes after brain cancer surgery	RE
Jun. 02	BSF Enterprise shares jump on paper in praise of "T-rex leather"	AN
Jun. 01	Bristol Myers Squibb Wins EU Approval for Opdivo Combination in Advanced Classical Hodgkin Lymphoma	MT
Jun. 01	Bristol Myers Gets Speedy FDA Review of Camzyos in Adolescents	DJ
Jun. 01	Bristol Myers Squibb announces Opdivo® (nivolumab) in combination with Avd receives expanded EU label with approval in frontline advanced classical Hodgkin lymphoma	RE
Jun. 01	U.S. FDA accepts for Priority Review Bristol-Myers Squibb's supplemental new drug application for Camzyos (mavacamten)	RE
Jun. 01	Bristol Myers Squibb Announces A Supplemental New Drug Application	CI
Jun. 01	Bristol Myers Squibb Announces Opdivo in Combination with Avd Receives Expanded Eu Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma	CI
May. 29	Bristol-Myers Squibb Company Presents Positive Phase 3 Results For Mezigdomide In Combination With Carfilzomib And Dexamethasone In Relapsed Or Refractory Multiple Myeloma	CI
May. 29	Jefferies Adjusts Price Target on Bristol-Myers Squibb to $73 From $70, Maintains Buy Rating	MT
May. 29	Bristol-Myers Squibb Says Mezigdomide Combination Cuts Myeloma Progression Risk in Phase 3 Trial	MT
May. 29	Bristol Myers Squibb says phase 3 Successor-2 trial shows MeziKd achieves 18-month median PFS	RE